Cardiovascular physiology and exercise
Dick Thijssen's research group focuses on the field of cardiovascular physiology and physical (in)activity. His work strongly focuses on understanding the impact of exercise training and physical activity on reducing the risk of developing cardiovascular and metabolic diseases.
Cerebral circulation and cognition in aging humans
Jurgen Claassen's research group uses various techniques to measure cerebral perfusion, cerebral autoregulation and cognitive activation. These physiological mechanisms play an important role in Alzheimer’s disease, hypertension, and cognitive aging.
Clinical neuroscience in psychiatry
Indira Tendolkar's group focuses the intersection between clinical psychiatry and cognitive neuroscience with a focus on declarative memory. We investigate the adapatation of emotional and neutral memory processes depending on genetic and environmental variablity including somatic challenges.
Clinical pharmacology - special populations
Saskia de Wildt's research group uses innovative methods including microdosing and microtracer technology, and physiology-based and population pharmacokinetic modeling, to contribute to a better understanding of the impact of age, disease and genetics on drug disposition in children.
Computational approaches to advance personalized medicine
Peter-Bram 't Hoen's research group develops computational approaches that exploit molecular -omics data in combination with clinical data to better understand disease mechanisms and to advance patient diagnosis and stratification for therapeutic and life style interventions.
Thijs Eijsvogels’s research group studies the acute and long-term effects of exercise on health. Current projects involve cardiac imaging following lifelong exercise training, optimizing cardiac rehab, assessing thermoregulatory responses in elite athletes and development of cooling strategies.
Genomic technologies & immuno-genomics
Alexander Hoischen's research group focuses on the application of latest genomic technologies to understand human disease. A particular emphasis is put in the understanding of genetic defects that explain immune diseases, in particular primary immunodeficiencies.
Magnesium in health and disease
Jeroen de Baaij's research group examines the role of magnesium in health and disease. Our mission is to decipher the pathophysiological mechanisms of magnesoium-wasting tubulopathies by development of novel disease models and advanced methods to measure magnesium transport.
Neurological movement disorders
Bas Bloem's first research line aims at studying human motor control in health and disease, in particular patients with neurological movement disorders. A second main interest is in health care innovation, aiming to develop and scientifically evaluate patient-centred collaborative care.
Pharmacology of antibiotic agents
Roger Brüggemann's and Nynke Jager's research group investigates the pharmacokinetics and dynamics of antimicrobial agents. Research ranges from in vitro experiments to clinical trials in special patient populations. The main aim is to define the optimal dose for each individual patient.
Pharmacology of anti-tuberculosis drugs
Rob Aarnoutse's research group investigates the pharmacology of existing and new drugs for tuberculosis, using a translational approach that extends from molecular pharmacology to clinical pharmacology studies and to clinical trials, supported by advanced laboratory and modeling techniques.
Pharmacology of antiviral drugs (HIV and HCV)
David Burger's group investigates the pharmacology of antiviral drugs for the treatment of HIV and hepatitis C in special patient population such as pregnant women, children and hepatically impaired patients. We also study drug-drug interactions and the impact on exposure of new drug-formulations.
Radboud applied pharmacometrics
Rob ter Heine's and Elin Svensson's research group develops and applies mathematical models describing clinical pharmacology processes to interpret clinical trial data, perform clinical trial simulations, support drug development decisions, and optimize therapy in the clinic.
Sander Leeuwenburgh's research group focuses on developing advanced tissue regenerative therapies, utilizing biomaterials either or not combined with biological components. These therapies exploit biomaterial properties, patient-derived cells or therapeutic molecules to empower their functionality.
Renal electrolyte handling
René Bindels' research group studies the regulation of ion transport processes in kidney and small intestine in health and disease. Current projects involve the molecular mechanisms underlying rare tubulopathies and the regulation of the newly identified calcium, magnesium and sodium transporters.
Roland Brock’s group focuses on the targeted delivery of molecules such as oligonucleotides, toxins and photosensitizers to modulate cell function and/or induce cell death. This research involves fundamental studies of formulation strategies and uptake mechanisms as well as preclinical applications.